net_left Phương Thức Thanh Toán
Phương Thức Thanh Toán

U.S. regulators defend requiring more data on monkeypox drug

By Julie Steenhuysen CHICAGO (Reuters) - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday defended their decision to require...
U.S. regulators defend requiring more data on monkeypox drug © Reuters. FILE PHOTO: Test tubes labelled "Monkeypox virus positive" are seen in this illustration taken May 23, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

By Julie Steenhuysen

CHICAGO (Reuters) - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday defended their decision to require human trial data to show that SIGA Technologies' experimental drug TPOXX is safe and effective to treat the virus.

U.S. agencies have been under pressure to ease access to the drug, which is being distributed by the U.S. Centers for Disease Control and Prevention (CDC) under a special "compassionate use" access that requires doctors to request it from the agency or their health department and enroll each patient in a study.

As of July 22, 223 people have been treated with the drug, compared with more than 6,000 known cases in the United States.

The FDA approved TPOXX in 2018 for smallpox in adults and children based on studies of animals infected with monkeypox and rabbitpox, as well as safety data in healthy people. It can only be sold to the U.S. Strategic National Stockpile.

Authors of the article in the New England Journal of Medicine from the Food and Drug Administration, the CDC and the National Institutes of Health (NIH) said the latter is planning a U.S.-based randomized clinical trial.

Data from that study will be used to determine whether the drug gains U.S. approval for monkeypox.

The drug, also known as tecovirimat, is approved for both smallpox and monkeypox in the UK and Europe. The European Union approved it under an "exceptional circumstances" pathway that allows for marketing approval when data cannot be obtained even after authorization.

Although TPOXX was only tested in healthy people, the European Medicines Agency said it expects side effects to be similar in infected people, and deemed the drug's benefits to be greater than its risks.

Dr. Jay Varma, director of the Cornell Center for Pandemic Prevention and Response who has advocated for broader access to the drug, said the FDA's standards ensure U.S. drugs are safe and set a high bar for the world, but in some circumstances, "those strict standards are harming us."

There were 1.7 million doses of the treatment in the U.S. Strategic National Stockpile at the start of the current outbreak in May.

On July 21, the CDC and the FDA began allowing doctors to prescribe the drug before the trial paperwork is completed, but still requires approval of a hospital's institutional review board for each dose.

"It's definitely better. It's still very burdensome," said Dr. Karen Krueger, an infectious disease expert at Northwestern (NASDAQ:NWE) Medicine in Chicago, who said there is additional paperwork after the patient visit and for several follow-up visits.

"It's doable but certainly a lot more challenging than how we normally prescribe drugs."

Neither the FDA nor the CDC immediately responded to a request for comment.

Northwestern has treated at least 20 monkeypox patients with TPOXX and will be one of the sites for the NIH trial.

To win approval, SIGA Chief Scientific Officer Dennis Hruby estimates it will likely take a 500-patient, placebo-controlled clinical trial in the United States.

If cases remain high, the trial could be fully enrolled within a few months. "It's not a terribly long trial," he said.

SIGA Chief Executive Phillip Gomez said the company is working to launch trials in the UK, Canada, the United States and Europe.

If the United States declares monkeypox a national emergency, Gomez said the drug could be granted an emergency use authorization. However, because the FDA has been "very clear" they want full, placebo-controlled trials, that could still take time, he said.

Hot Auto Trade Bot Phương Thức Thanh Toán
BROKERS ĐƯỢC CẤP PHÉP
net_home_top Ai VIF
13-08-2022 01:00:38 (UTC+7)

EUR/USD

1.0261

-0.0056 (-0.54%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (3)

Sell (1)

EUR/USD

1.0261

-0.0056 (-0.54%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (3)

Sell (1)

GBP/USD

1.2141

-0.0072 (-0.59%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

USD/JPY

133.49

+0.49 (+0.36%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (2)

Sell (6)

AUD/USD

0.7121

+0.0015 (+0.22%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (2)

Sell (5)

USD/CAD

1.2780

+0.0019 (+0.14%)

Summary

↑ Buy

Moving Avg:

Buy (9)

Sell (3)

Indicators:

Buy (8)

Sell (0)

EUR/JPY

136.98

-0.24 (-0.17%)

Summary

Buy

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (7)

Sell (2)

EUR/CHF

0.9668

-0.0037 (-0.38%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (6)

Sell (3)

Gold Futures

1,815.15

+7.95 (+0.44%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (7)

Silver Futures

20.703

+0.354 (+1.74%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (0)

Sell (6)

Copper Futures

3.6695

-0.0370 (-1.00%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (6)

Sell (3)

Crude Oil WTI Futures

92.49

-1.85 (-1.96%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

Brent Oil Futures

98.33

-1.27 (-1.28%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

Natural Gas Futures

8.810

-0.064 (-0.72%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

US Coffee C Futures

227.53

+3.58 (+1.60%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

Euro Stoxx 50

3,776.81

+19.76 (+0.53%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (2)

Sell (6)

S&P 500

4,256.70

+49.43 (+1.17%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (10)

Sell (0)

DAX

13,795.85

+101.34 (+0.74%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (2)

Sell (4)

FTSE 100

7,500.89

+34.98 (+0.47%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (3)

Sell (2)

Hang Seng

20,175.62

+93.19 (+0.46%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

US Small Cap 2000

2,003.90

+27.20 (+1.38%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (8)

Sell (1)

IBEX 35

8,400.40

+20.40 (+0.24%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (6)

BASF SE NA O.N.

44.155

+0.730 (+1.68%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (6)

Sell (2)

Bayer AG NA

54.15

+2.47 (+4.78%)

Summary

↑ Buy

Moving Avg:

Buy (9)

Sell (3)

Indicators:

Buy (9)

Sell (0)

Allianz SE VNA O.N.

181.08

+2.08 (+1.16%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (3)

Sell (6)

Adidas AG

173.20

+1.18 (+0.69%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

Deutsche Lufthansa AG

6.588

+0.062 (+0.95%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (2)

Sell (6)

Siemens AG Class N

111.84

+1.92 (+1.75%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Deutsche Bank AG

9.061

+0.197 (+2.22%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (5)

Sell (0)

 EUR/USD1.0261↑ Buy
 GBP/USD1.2141↑ Buy
 USD/JPY133.49↑ Sell
 AUD/USD0.7121Neutral
 USD/CAD1.2780↑ Buy
 EUR/JPY136.98Buy
 EUR/CHF0.9668↑ Buy
 Gold1,815.15↑ Sell
 Silver20.703↑ Sell
 Copper3.6695↑ Buy
 Crude Oil WTI92.49↑ Buy
 Brent Oil98.33↑ Buy
 Natural Gas8.810↑ Buy
 US Coffee C227.53↑ Buy
 Euro Stoxx 503,776.81Sell
 S&P 5004,256.70↑ Buy
 DAX13,795.85Neutral
 FTSE 1007,500.89Neutral
 Hang Seng20,175.62↑ Buy
 Small Cap 20002,003.90↑ Buy
 IBEX 358,400.40↑ Sell
 BASF44.155↑ Buy
 Bayer54.15↑ Buy
 Allianz181.08↑ Sell
 Adidas173.20↑ Buy
 Lufthansa6.588↑ Sell
 Siemens AG111.84↑ Sell
 Deutsche Bank AG9.061↑ Buy
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,620/ 6,720
(0/ 0) # 1,655
SJC HCM6,630/ 6,730
(0/ 0) # 1,663
SJC Hanoi6,630/ 6,732
(0/ 0) # 1,665
SJC Danang6,630/ 6,732
(0/ 0) # 1,665
SJC Nhatrang6,630/ 6,732
(0/ 0) # 1,665
SJC Cantho6,630/ 6,732
(0/ 0) # 1,665
Cập nhật 13-08-2022 01:00:41
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,799.31+10.160.57%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩmVùng 1Vùng 2
RON 95-V25.34025.840
RON 95-III24.66025.150
E5 RON 92-II23.72024.190
DO 0.05S22.90023.350
DO 0,001S-V24.88025.370
Dầu hỏa 2-K23.32023.780
ↂ Giá dầu thô thế giới
WTI$91.95+1.421.52%
Brent$97.65+0.960.97%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD23.220,0023.530,00
EUR23.498,0024.813,92
GBP27.761,8728.945,83
JPY170,70180,72
KRW15,5018,89
Cập nhật lúc 18:51:42 12/08/2022
Xem bảng tỷ giá hối đoái
Phương Thức Thanh Toán